1. CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. (3rd June 2020) Authors: Qian, Jie‐Jing; Hu, Xiaoxia; Wang, Ying; Zhang, Yi; Du, Juan; Yang, Min; Tong, Hongyan; Qian, Wen‐Bin; Wei, Juying; Yu, Wenjun; Lou, Yin‐Jun; Mao, Liping; Tao Meng, Hai; You, Liang‐Shun; Wang, Libing; Li, Xia; Huang, Xin; Cao, Li‐Hong; Zhao, Jian‐Zhi; Yan Yan, Xiao Journal: Cancer medicine Issue: Volume 9:Number 15(2020) Page Start: 5327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical and biological characteristics of acute myeloid leukemia with 20–29% blasts: a retrospective single-center study. Issue 5 (16th April 2019) Authors: Mei, Chen; Ren, Yanling; Zhou, Xinping; Ye, Li; Ma, Liya; Luo, Yingwan; Lin, Peipei; Xu, Weilai; Lu, Chenxi; Yang, Haiyang; Yu, Wenjuan; Mao, Liping; Wei, Juying; Jin, Jie; Tong, Hongyan Journal: Leukemia & lymphoma Issue: Volume 60:Issue 5(2019) Page Start: 1136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical Significance of Prognostic Nutritional Index for Patients with Diffuse Large B-cell Lymphoma. (19th May 2019) Authors: Yu, Wenjuan; Guo, Qi; Wang, Zhaoming; Mao, Liping; Wei, Juying; Jin, Jie; Wang, Jinghan Journal: Nutrition and cancer Issue: Volume 71:Number 4(2019) Page Start: 569 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. Issue 1 (1st January 2019) Authors: Tang, Huifen; Zhou, Hui; Wei, Juying; Liu, Hui; Qian, Wenbin; Chen, Xiaohui Journal: Hematology Issue: Volume 24:Issue 1(2019) Page Start: 446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial. Issue 4 (24th June 2020) Authors: Zhou, Xinping; Mei, Chen; Zhang, Jin; Lu, Ying; Lan, Jianping; Lin, Shengyun; Zhang, Yuefeng; Kuang, Yuemin; Ren, Yanling; Ma, Liya; Wei, Juying; Ye, Li; Xu, Weilai; Li, Kongfei; Lu, Chenxi; Jin, Jie; Tong, Hongyan Journal: Hematological oncology Issue: Volume 38:Issue 4(2020) Page Start: 531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China. Issue 3 (22nd January 2021) Authors: Wang, Shuo; Wang, Li; Hu, Jianda; Qian, Wenbin; Zhang, Xi; Hu, Yu; Zhu, Qi; Chen, Bobin; Wu, Depei; Chang, Chung‐Chou H.; Xu, Pengpeng; Zheng, Xiaoyun; Wei, Juying; Liu, Yao; Cui, Guohui; Tang, Yong; Ma, Yan; Huang, Haiwen; Yi, Hongmei; Zhao, Weili Journal: Cancer communications Issue: Volume 41:Issue 3(2021) Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre. Issue 2 (February 2018) Authors: Wang, Huafeng; Wang, Ming; Wei, Juying; Wang, Lei; Mao, Liping; Jin, Jie Journal: Journal of international medical research Issue: Volume 46:Issue 2(2018) Page Start: 883 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Prognostic effects of clinical parameters, genetic abnormalities, and subtypes in primary gastric diffuse large B-cell lymphoma: a cohort analysis of 146 patients. Issue 14 (6th December 2022) Authors: Liu, Junqing; Wei, Juying; Jiang, Xue; Yu, Wenjuan; Tong, Hongyan; Jin, Jie; Yan, Senxiang; Xu, Weilai Journal: Leukemia & lymphoma Issue: Volume 63:Issue 14(2022) Page Start: 3362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Issue 1 (December 2017) Authors: Hu, Chao; Yu, Mengxia; Ren, Yanling; Li, Kongfei; Maggio, Dominic; Mei, Chen; Ye, Li; Wei, Juying; Jin, Jie; Zhuang, Zhengping; Tong, Hongyan Journal: Scientific reports Issue: Volume 7:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Issue 6 (June 2022) Authors: Wang, Huafeng; Mao, Liping; Yang, Min; Qian, Pengxu; Lu, Huan; Tong, Hongyan; Xie, Wanzhuo; Zhou, De; Huang, Xin; Wang, Yungui; Xu, Gaixiang; Lu, Ying; Wei, Juying; Mai, Wenyuan; Ye, Xiujin; Meng, Haitao; Shen, Yaojia; Huang, Jian; Yu, Wenjuan; Sun, Jie Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗